Method of Treatment Claims Are Not Invalid for Lacking Written Description or Enablement Simply Because the Treatment Is Not Safe or Efficacious in Some Patients

July 26, 2023

Congress Seeks to Eliminate the Judicial Exceptions to Patent Eligibility

June 28, 2023

Will the Supreme Court Reevaluate the Subject Matter Eligibility of Diagnostic Claims?

June 1, 2023

Now What? The Supreme Court Addresses Enablement

June 1, 2023

Incorporated References Can Be Used in an Anticipation Rejection

April 19, 2023

U.S. Electronic Patent Grants and the Effect on the Timing of Filing Continuation and Divisional Patent Applications

March 10, 2023

The Supreme Court Again Declines to Address the Written Description Standard

January 11, 2023

Juno Therapeutics Requests That the Supreme Court Wait to Make a Decision on Its Written Description Question Until Amgen’s Enablement Case Is Resolved

November 30, 2022

Supreme Court Denies Review of the Written Description Requirement

November 16, 2022

Supreme Court to Address What it Means to Have an Enabling Disclosure

November 8, 2022